4.5 Article

Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children

Journal

JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
Volume 49, Issue 1, Pages 376-382

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10803-018-3721-8

Keywords

Risk factor; Opioid; ASD; Developmental disorder; Pregnancy

Funding

  1. Centers for Disease Control and Prevention (CDC) [U10DD000180, U10DD000181, U10DD000182, U10DD000183, U10DD000184, U10DD000498]
  2. Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health [T32HD007489, U54 HD090256]

Ask authors/readers for more resources

Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child's risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available